TSHA vs. KNSA, RCUS, OCUL, MRVI, ARVN, CALT, DAWN, PRAX, ANIP, and SPRY
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Maravai LifeSciences (MRVI), Arvinas (ARVN), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), Praxis Precision Medicines (PRAX), ANI Pharmaceuticals (ANIP), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.
Taysha Gene Therapies vs.
Taysha Gene Therapies (NASDAQ:TSHA) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
Taysha Gene Therapies has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.
Kiniksa Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 2.7% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Taysha Gene Therapies' net margin of -229.67%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Taysha Gene Therapies' return on equity.
Taysha Gene Therapies presently has a consensus target price of $6.63, suggesting a potential upside of 333.01%. Kiniksa Pharmaceuticals has a consensus target price of $36.60, suggesting a potential upside of 97.41%. Given Taysha Gene Therapies' higher possible upside, research analysts clearly believe Taysha Gene Therapies is more favorable than Kiniksa Pharmaceuticals.
In the previous week, Kiniksa Pharmaceuticals had 19 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 21 mentions for Kiniksa Pharmaceuticals and 2 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Kiniksa Pharmaceuticals' score of 0.53 indicating that Taysha Gene Therapies is being referred to more favorably in the media.
Kiniksa Pharmaceuticals received 66 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 77.21% of users gave Taysha Gene Therapies an outperform vote while only 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote.
Summary
Taysha Gene Therapies beats Kiniksa Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:TSHA) was last updated on 1/18/2025 by MarketBeat.com Staff
Free TSHA Stock Alerts